Promoter Acquirer Increases Stake in Goldline Pharmaceutical Ltd Through Open Market Purchase
Swapan Khandelwal, a Whole Time Director and Promoter of Goldline Pharmaceutical Limited, has increased his stake in the company following an open market purchase on June 22, 2026.The promoter acquired 60,000 equity shares of Goldline Pharmaceutical Limited. This transaction represents 0.62% of the total paid-up shares capital of the company.
Prior to the acquisition, Mr. Khandelwal's holding stood at 2,749,988 shares, equating to 28.65% of the company’s total paid-up share capital.
Following the purchase, his cumulative holding increased to 2,809,988 shares, which corresponds to a 29.27% stake in Goldline Pharmaceutical Limited.
The details of the acquisition and holdings are summarized below:
| Detail | Before Acquisition | Transaction Details | After Acquisition |
|---|---|---|---|
| Number of Shares Held (Voting Rights) | 2,749,988 | Acquired 60,000 | 2,809,988 |
| Percentage of Total Share Capital | 28.65% | 0.62% in Open Market Purchase | 29.27% |
The total equity share capital and voting capital of Goldline Pharmaceutical Limited remained at 9,600,000 Equity Shares both before and after the said acquisition.
Stock Price Movement
As of 13:21, Goldline Pharmaceutical Ltd's stock is ticking lower, with shares currently trading at ₹44.32 after a decline of 4.83%. The company's shares have since fluctuated throughout the session, finding their range between an intraday low of ₹44.25 and a high of ₹45.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.